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Background: Ginsenosides are the main ingredients of ginseng, which, in traditional Eastern medicine,
has been claimed to have therapeutic values for many diseases. In order to verify the effects of ginseng
that have been empirically observed, we utilized the reverse docking method to screen for target pro-
teins that are linked to speciﬁc diseases.
Methods: We constructed a target protein database including 1,078 proteins associated with various
kinds of diseases, based on the Potential Drug Target Database, with an added list of kinase proteins. We
screened 26 kinds of ginsenosides of this target protein database using docking.
Results: We found four potential target proteins for ginsenosides, based on docking scores. Implications
of these “hit” targets are discussed. From this screening, we also found four targets linked to possible side
effects and toxicities, based on docking scores.
Conclusion: Our method and results can be helpful for ﬁnding new targets and developing new drugs
from natural products.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Korean ginseng is well known as a medicinal herb that has
widely been used in the traditional medicine ﬁeld. Ginseng has
pharmacological actions because of the saponin ginsenoside, about
40 types of which have been found. Depending on the method of
production, ginseng can be classiﬁed into white ginseng (Ginseng
Radix Alba) and red ginseng (Ginseng Radix Rubra). White ginseng
is produced by air drying fresh ginseng, whereas red ginseng is
produced by ﬁrst steaming fresh ginseng and then air drying it [1].
Owing to this difference in production methods, red ginseng con-
tains more Rg1 and Rb1 ginsenosides than white ginseng.
Virtual screening, which has become a de facto standard in
modern-day drug discovery, is a computational method for iden-
tifying potent molecules binding to a speciﬁc target protein from a
large and chemically diverse molecule library [2]. It is a one-target
many-ligand concept [3]. Virtual screening-based drug designs
have successfully resulted in some approved drugs in recent his-
tory. Central to virtual screening is a computational method called
docking [4]. A docking program predicts the binding mode of a
small molecule/target protein complex. In order to ﬁnd the most
plausible binding modes, a docking program ranks possible con-
formations using a scoring function.tics, Korea University, 2511 Sejong
ht  2016, The Korean Society of G
d/4.0/).
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jgr.2016.10.005Reverse docking is a recent method that does the opposite of
virtual screening through the use of docking. One screens a database
of target proteins against an active compounddthe one-ligand
many-target concept, and just as in virtual screening, uses docking
to ﬁnd correct binding modes for ligandetarget protein complexes
[3]. However, in reverse docking, target proteins for a given ligand
rather than ligands for a given target protein are ranked. Utilizing
the list of ranked target proteins, the relevance of a given ligand for
particular diseases or its side effects can be estimated. Therefore, the
reverse dockingmethod is useful for drug repositioning [5], inwhich
one looks for new targets of drugs already approved or of natural
products the exact effects of which are not yet known [6].
Ginsenosides are known to have many therapeutic values: they
have antiallergic, antioxidant, and immune-stimulatory properties,
and can modulate blood pressure, metabolism, and immune func-
tions. Ginsenosides are named according to their retention factor
value in thin-layer chromatography. Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rg5,
Rh2, Rh3, Rs3, and compound K are 20(S)-protopanaxadiols, and
Re, Rf, Rg1, Rg2, Rg4, Rh4, and Rh5 are 20(S)-protopanaxatriols [7].
Furthermore, several ginsenosides, such as the ocotillol saponins
F2, F3, F5, and F11 [8] and the pentacyclic oleanane saponin Ro [9]
have also been identiﬁed. Recent studies have linked these ginse-
nosides to multiple bioactivities including neuroprotection,-ro, Sejong 30019, South Korea.
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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J Ginseng Res 2016;-:1e62antioxidation, angiogenesis modulation, and cytotoxicity [10]. In
this work, we utilized the reverse docking technique to elucidate
and/or conﬁrm therapeutic values and side effects of ginsenosides
by screening a target protein database against them. Chen et al [11]
have used a reverse docking method, called INVDOCK, to extract
possible drug targets by predicting interactions between com-
pounds including ginsenoside Rg1, which are found in medicinal
plants, and human and mammalian proteins. However, in order to
fully assess the therapeutic values of ginseng, one needs to analyze
the full array of ginsenosides. We also utilizedmore comprehensive
target protein databases developed recently. In terms of the reverse
docking method, INVDOCK is proprietary and little is known about
its performance as a docking method. In our work, the well-known
commercial docking program Glide (version 6.7; Schrödinger, Inc.,
New York, NY, USA) was used as part of our protocol, making it easy
to replicate. In addition to potential drug targets, we also examined
interactions of ginsenosides with toxicity- and side effect-related
target proteins. Details of the methodology are described in the
Materials and methods section. Our analysis of the targets, which
were found to interact with ginsenosides, is summarized in the
Results section. Our results not only validate the previously iden-
tiﬁed therapeutic values of ginsenosides, but also give insights into
the overlooked ones.
2. Materials and methods
2.1. Construction of drug target database
In this work, we used the Potential Drug Target Database (PDTD)
as our drug target database [12,13]. The PDTD contains 1,207 entries
covering 841 known and potential drug targets with known three-
dimensional structures presented in the Research Collaboratory for
Structural Bioinformatics (RCSB) Protein Data Bank. The target
proteins collected in the PDTD were selected from the literature
and online databases, such as DrugBank and the Therapeutic Target
Database [13]. We selected 529 entries, which are classiﬁed as
therapeutic in the PDTD, and then constructed a drug target data-
base for reverse docking. Furthermore, 549 kinase targets were
collected from an online database and added to the drug target
database [14]. Diseases related to the targets in our database are
bacterial/fungal/viral/parasitic infections, blood and neuronal dis-
orders, inﬂammation, renal disorders, cardiovascular disorders,
gastrointestinal disorders, cancer, and kinase-related disorders
(Table 1). Each record of a target was annotated by hyperlinks to
other databases, such as DrugBank, Therapeutic Target Database,
the Expert Protein Analysis System (ExPASy) proteomics server, and
Kyoto Encyclopedia of Genes and Genomes (KEGG).Table 1
Diseases related to target proteins in our database1)
(1) Bacterial infections (44)
(2) Diseases of the blood & blood-forming organs (51)
(3) Fungal infections (9)
(4) Disorders of gastrointestinal functions (15)
(5) Hormone- & hormone antagonist-related diseases (82)
(6) Immunomodulation (45)
(7) Inﬂammation (24)
(8) Neoplastic diseases (85)
(9) Parasitic infectious diseases (27)
(10) Renal & cardiovascular disorders (30)
(11) Diseases of the synaptic & neuroeffector junctional sites,
central nervous system (25)
(12) Vitamin deﬁciency diseases (25)
(13) Viral infections (67)
(14) Kinase-related disorders (549)
1) Numbers in parentheses indicate how many of the targets are in our database
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In addition to the disease-related targets fromPDTD,we included
proteins that are linked to side effects and toxicities based on avail-
able data from the medical biochemistry literature. It is well known
that the inhibition of some proteins important in normal cellular
functionmay result in toxicity or side effects [15]. These proteins are
involved in important cellular metabolism processes such as amino
acid andnucleotidemetabolism, theglycolytic pathway, and theurea
cycle. There are 73 Protein Data Bank (PDB) entries for 20 types of
proteins connected to toxicities and side effects.
2.3. Preparation of ginsenoside ligand and target structure
We prepared 26 kinds of ginsenoside structures [7] with known
structures presented in the PubChem [16]. The structures were
generated by the two-dimensional Sketcher inMaestro, after which
LigPrep (version 3.4; Schrödinger Inc., New York, NY, USA) was used
to convert them into three-dimensional structures. During the
preparation, the force ﬁeld was set to OPLS-2005, and all the com-
binations of stereoisomers were generated. They were assigned
protonation states at pH 7.0. Our target database contained 1,078
protein structures, and the cocrystal complexes were downloaded
from the RCSB Protein Data Bank. Missing residues and atoms of
each protein structure were repaired using the Schrödinger Protein
Preparation Wizard. The Protein Preparation Wizard automatically
ﬁxes incomplete residues and determines the tautomeric states of
histidine, glutamine, and asparagine residues. Water molecules and
cofactorswere removed except for ones inﬂuencing the binding site.
Hydrogen atoms were added, and the positions were optimized to
0.3 Å root-mean square deviation (RMSD) with heavy atoms ﬁxed.
2.4. Reverse docking using Glide
All the reverse dockings in this research were performed with
Schrödinger’s Glide (version 6.7; Schrödinger Inc.). We used the
standard precision mode of Glide, which is efﬁcient and accurate
for most of the targets [17,18]. Glide generates the possible binding
modes of ligandeprotein complexes and scores them with Glide-
Score, a mixture of interaction energy and parameter-based penalty
functions that roughly represents binding energy. The reverse
docking procedure was performed as follows: (1) using a Python
script, we generated an input ﬁle for each of the 26 kinds of gin-
senosides for docking with all the target proteins in our database;
(2) using Glide, each ginsenoside was docked to all 1,078 target
proteins; and (3) docking results were sorted by docking scores and
arranged into a matrix form. The resulting docking proﬁles were
clustered for further analysis.
3. Results
3.1. Reverse docking results
To identify the efﬁcacy of the 26 kinds of ginsenosides, we
performed reverse docking with a database of 1,078 target proteins.
For a detailed analysis, we clustered the entire docking results by
scores. Fifty-two percent of all target proteins were docked by one
or more of the 26 ginsenosides. Rh4, in particular, interacted with
72% of the targets. The average GlideScore of the docked results
was 5.285 kcal/mol. Rc had an average of 6.249 kcal/mol across
all the docked targets, which was the highest. In addition, 336
target proteins interacted with more than 21 ginsenosides, which
suggested that several ginsenosides can have activities toward a
single target. For further analysis as to what kind of implications
these data might have on the therapeutic value of ginsenosides, weg to identify potential targets for ginsenosides, Journal of Ginseng
Table 3
Comparison of docking scores between ginsenoside Rh4 and native ligands docked
to MEK1 proteins
PDB ID Native ligand1) Rh4
Docking score Docking score
2P55 6.706 9.0199
3DY7 6.887 9.797
3E8N 7.692 11.158
3EQB 5.45 9.955
3EQC 6.163 9.168
3EQH 9.175 9.258
3MBL 8.253 11.28
3OS3 7.278 11.143
3PP1 7.692 9.457
1) PDB and cocrystal ligand redocking scores
Table 4
Interactions of EGFR and mutant EGFR target proteins with ginsenosides
Type PDB ID Ginsenoside Interacting residues
Type Docking score
Wild 2GS6 Rb2 8.991 MET769, GYS773, GLU734
Rb3 8.232 ASP776, MET769, LYS889, GLU738
Ro 8.105 CYS773, ASP813, GLU738
2ITX R2 10.090 GLY724, LYS745, PRO794
2ITY Rb2 8.071 ARG841, ASN842, GLU804
L858R 2EB3 R2 8.197 MET793, GLU762, ASP800
Rf 8.295 MET793, ASP800, GLU762, ASP855
2ITU Rg1 8.987 CYS797, GLN791, GLY724
Rg3 8.047 GLN791, Pro794,
Ro 8.447 LYS728, GLN791, PRO794
2ITZ Rb2 8.294 PRO794, ASP855, LYS716
G719S 2ITN R2 8.037 GLY724, LYS745, ASP837, MG
2ITO Ro 8.224 ARG841, ASP855, PHE795
2ITP Rc 9.622 PRO794, ASP800
EGFR, epidermal growth factor receptor
K. Park and A.E. Cho / Reverse docking study of ginsenosides 3calculated the binding energy of each target protein’s native ligand
to compare it with the binding energies of the ginsenosides.
3.2. Identiﬁcation of therapeutic targets
In order to identify speciﬁc targets related to diseases for which
ginsenosides can be therapeutic, we compared the binding energies
of ginsenosides with those of native ligands. In Table 2, the top 10
targets for each ginsenoside are listed. We also checked if these
targets were experimentally found to be associated with ginseno-
sides. There were 63 cases in which the binding energies of ginse-
nosideswerebelowboth thoseofnative ligandsand8kcal/mol.We
selected four potential targets for ginsenosides based on their fre-
quencyof showing as targets for eachginsenoside and thenumberof
ginsenosides that interacted with each target. These cases exhibited
therapeutic targets for which ginsenosides could be effective.
The target with which ginsenosides interacted most was
mitogen-activated protein kinase 1 (MEK1). Ten different MEK1
proteins out of 16 in the target database had signiﬁcant interactions
with at least one ginsenoside, and 11 ginsenosides were involved in
these interactions for a total of 28 interactions. MEK1 is known to
be linked to cell proliferation in most colon cancer cells and thus
has received attention as a new target for anticancer drugs treating
colorectal cancer [23]. Experimentally, ginsenoside Rg3 was found
to be effective for MEK1 [19]. Our docking study found other gin-
senosides that are effective as well. In particular, ginsenoside Rh4
was shown to be highly interactive with 10 MEK1 proteins, with an
average docking score of 10.077 kcal/mol (Table 3).
The next most active was epidermal growth factor receptor
(EGFR). Nine different EGFR proteins interacted signiﬁcantly with
eight ginsenosides. EGFR has been identiﬁed as an oncogene, and
its inhibitors have been developed for anticancer therapeutics,
examples of which include geﬁtinib, erlotinib, afatinib, brigatinib,
and icotinib for lung cancer, and cetuximab for colon cancer.
However, these inhibitors turned out to be ineffective against
mutant EGFRs, and for this reason, natural compounds have been
studied as EGFR inhibitors [24]. Li et al [25] showed that ginseno-
side Rh2 can substantially inhibit the growth of glioblastoma
in vitro and in vivo in a mousemodel. In glioblastoma, a more or less
speciﬁc mutation of EGFR, EGFRvIII, is often observed. Furthermore,
Sathishkumar et al [20] identiﬁed 14 compounds of Panax ginseng
that can be developed as EGFR tyrosine kinase inhibitors using
pharmacophore modeling and molecular docking. In our docking
study, not only thewild type of EGFR, but also two types of mutants,
L858R and G719S, showed interactions with ginsenosides (Table 4).
The average docking score between EGFR and 14 ginsenosides
was 8.546 kcal/mol. In Fig. 1A, binding pose interaction diagrams
of complexes of EGFR wild-type protein (PDB ID: 2ITX) with the
native ligand (ANP) at the top and with ginsenoside R2 at theTable 2
Top 10 potential targets of ginsenosides according to docking scores
PDB ID Target name Native lig
Docking sc
3OS3 Dual speciﬁcity mitogen-activated protein kinase kinase 1 7.278
3O96 RAC-alpha serine/threonine-protein kinase 10.83
1MCH Immunoglobulin lambda light chain dimer (Mcg) 7.988
2ITX Epidermal growth factor receptor precursor 5.256
1TUI Elongation factor 1-alpha 8.649
1ETT Thrombin 8.384
3FGU Glucokinase 3.853
1DHT Estrogenic 17-beta hydroxysteroid dehydrogenase 5.785
2PVR Casein kinase II subunit alpha 5.499
1OL6 Aurora kinase A 8.342
1) Docking scores from redocking of receptor proteins and native ligands of PDB entrie
2) Whether or not there is an experimental result of the particular ginsenosides and th
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native ligand ANP interacts with LYS745 and MET793, and ginse-
noside R2 makes the same contact as ANP, but also makes addi-
tional contacts with a few surrounding residues including PRO794.
This comparison is consistent with the calculated binding afﬁnity
score, for which R2 doubled ANP (Table 4).
Twelve kinds of ginsenosides interacted with the serine prote-
ase thrombin, which has received much attention due to its central
role in the initiation of blood coagulation and hemostatic disorder
[26]. Zhou et al [21] suggested that Rg1 could serve as a good
resource for the screening and development of novel therapeutic
agents for thrombotic disorders. In accordance with the experi-
mental results, our docking study showed that the thrombin target
protein interacts with Rg1, with a docking score of9.566 kcal/mol.and Ginsenoside Implicated by experiment2) Reference
ore1) Type Docking score
Rf 12.681 Yes [19]
6 Rs3 11.394 No
Rf 10.217 No
R2 10.090 Yes [20]
Ro 9.718 No
Rg1 9.566 Yes [21]
Ro 9.346 Yes [22]
Rh5 9.306 No
R2 9.240 No
Re 9.211 No
s
e target in the literature
g to identify potential targets for ginsenosides, Journal of Ginseng
Fig. 1. Binding mode diagrams between target proteins and native ligands or ginsenosides. EGFR protein (PDB ID: 2ITX): (A) 2ITX-ANP, docking score 8.637 kcal/mol; (B) 2ITX-
ginsenoside R2, docking score 10.090 kcal/mol, and Aurora kinase A protein (PDB ID: 1OL5); (C) 1OL5-ADP, docking score 7.979 kcal/mol; and (D) 1OL5-ginsenoside F3, docking
score 8.480 (kcal/mol). EGFR, epidermal growth factor receptor.
J Ginseng Res 2016;-:1e64In addition, four kinds of serine proteinase alpha-thrombin target
proteins and 10 kinds of ginsenosides showed higher interaction
energies than native ligands, implying that they could be good
targets for ginsenosides (Table 5).Table 5
Comparison of docking scores between ginsenosides and native ligands docked to
thrombin and Aurora kinase A target proteins
Target name PDB ID Native ligand1)
docking score
Ginsenoside
Type Docking score
Serine protease thrombin 1ETR 6.202 Rg1 9.055
1ETT 8.384 Rg1 9.566
Serine proteinase
alpha-thrombin
1A4W 7.177 La 8.802
Rb2 8.321
F5 8.153
1AE8 6.427 Rg1 8.902
1DWC 6.613 CK 8.409
Rb1 8.329
Rh3 8.329
Re 8.311
R2 8.254
4THN 7.264 A1 8.131
Aurora kinase A 1OL5 7.979 A1 9.014
F3 8.48
Rg2 8.13
1OL6 8.342 Re 9.211
2W1C 7.005 R2 8.559
2W5B 8.03 Ro 8.235
2XRU 7.778 Rg5 8.168
1) PDB and cocrystal ligand redocking scores
Please cite this article in press as: Park K, Cho AE, Using reverse dockin
Research (2016), http://dx.doi.org/10.1016/j.jgr.2016.10.005Ginsenosides also interacted with Aurora kinase A, which is a
member of the serine/threonine kinase family. It plays an impor-
tant role in completing mitotic events such as centrosome sepa-
ration, biopolar spindle assembly, chromosome segregation, and
cytokinesis [27]. Dysregulation of Aurora kinase A may lead to
cancer because it is required for the completion of cytokinesis.
Thus, Aurora kinase A has been identiﬁed as a potential anticancer
drug target [28]. Our docking study showed that seven different
ginsenosides interacted with four Aurora kinase A proteins, with an
average docking score of 8.543 kcal/mol (Table 5). In case of
Aurora kinase A target protein, no experimental results related to
ginsenosides were found in the literature. However, an analysis of
the binding poses of the native ligand and ginsenoside F3 in the
binding site of Aurora kinase A target protein gave some clues as to
whether or not ginsenosides can be an effective binder. In Fig. 1,
ADP, which is the native ligand of Aurora kinase A protein (PDB ID:
1OL5), interacts strongly with LYS162 and magnesium metal ion.
Ginsenoside F3 interacts with a few other residues as well as
LYS162 and magnesium. The implication is that ginsenoside F3
binds to Aurora kinase A protein more strongly than the native
ligand, as our prediction of binding scores also indicate.
3.3. Potential toxicity and side effects of ginsenosides
In order to identify potential side effects and toxicity of ginse-
nosides, we selected 73 targets from 20 kinds associated with
toxicity and side effects, and examined their interaction with gin-
senosides (Table 6). Acetylcholinesterase interacted with 25g to identify potential targets for ginsenosides, Journal of Ginseng
Table 6
Toxicity and side effect protein targets of ginsenosides identiﬁed by reverse docking
Protein Physiological function Effect of deﬁciency/inhibition Docking score
Acetylcholinesterase Neurotransmission Cholinergic toxicity 5.056
Intestinal fatty acid binding protein Lipid uptake Altered distribution of lipid
proﬁle & adipogenesis
8.502
Carbonic anhydrase, types II & IV pH regulation in the
blood & kidney
Nephrotoxicity 5.974
Glutamate dehydrogenase Amino acid degradation Nephrotoxicity 5.406
K. Park and A.E. Cho / Reverse docking study of ginsenosides 5ginsenosides (all except for Re), with an average docking score
of5.056 kcal/mol. The inhibition of acetylcholinesterase is related
to cholinergic toxicity [29]. Ginsenosides Rh4, Rh5, and CK showed
signiﬁcant interaction with intestinal fatty acid-binding protein (I-
FABP), with an average docking score of 8.502 kcal/mol. If intes-
tinal fatty acid-binding protein is inhibited, triglyceride accumu-
lation declines and as a result, normal adipogenesis is suppressed
[30]. Carbonic anhydrase type II (CA II) was predicted to interact
with 26 ginsenosides in our docking results, with an average
docking score of 5.974 kcal/mol. The inhibition of CA II is known
to cause nephrotoxicity since CA is a key enzyme that regulates the
bicarbonate level in the blood [15]. Glutamate dehydrogenase was
also shown to interact with ginsenoside Rh4, with a docking score
of 6.614 kcal/mol. Glutamate dehydrogenase plays important
roles in amino acidmetabolism, and thus its inhibition could lead to
nephrotoxicity [31].4. Discussion
In this study, potential targets of ginsenosides were identiﬁed by
reverse docking. Among them, MEK1, EGFR, and Aurora A, which
are anticancer targets, were found to interact with ginsenosides
with high binding afﬁnity. In addition, thrombin, which is related to
blood coagulation, was found to be highly interactive with ginse-
nosides. In summary, claims of anticancer properties of ginseno-
sides were in part veriﬁed [32] as well as therapeutic effects against
heart diseases due to blood-thinning properties [33].
We also identiﬁed possible side effects/toxicities of ginsenosides
by reverse docking. Acetylcholinesterase inhibition, which can lead
to cholinergic toxicity, was found to be a possible effect of ginse-
nosides. CA II and glutamate dehydrogenase were also shown to
bind ginsenosides, which could lead to nephrotoxicities. Intestinal
fatty acid-binding protein was also found to be affected by ginse-
nosides; its inhibition could suppress adipogenesis. However, this
effect could sometimes be regarded as therapeutic, especially when
applied to obesity.
Further studies, including in vitro and in vivo experiments for the
targets identiﬁed from our investigation, are warranted to conﬁrm
our ﬁndings. Such endeavors would not only afﬁrm conventional
beliefs about ginsenosides’ therapeutic values, but also pave the
way to developing new drugs from natural products.Conﬂicts of interest
All authors declare no conﬂicts of interest.Acknowledgments
This work was supported by National Research Foundation of
Koreagrants (No. 2013R1A2A2A01067638 andNo. 2012M3C1A6035
362).We also thank Schrödinger, LLC, for providing software for our
research.Please cite this article in press as: Park K, Cho AE, Using reverse dockin
Research (2016), http://dx.doi.org/10.1016/j.jgr.2016.10.005References
[1] Nocerino E, Amato M, Izzo AA. The aphrodisiac and adaptogenic properties of
ginseng. Fitoterapia 2000;71:S1e5.
[2] Paul N, Kellenberger E, Bret G, Muller P, Rognan D. Recovering the true targets
of speciﬁc ligands by virtual screening of the protein data bank. Proteins
Struct Funct Bioinform 2004;54:671e80.
[3] Kharkar PS, Warrier S, Gaud RS. Reverse docking: a powerful tool for drug
repositioning and drug rescue. Fut Med Chem 2014;6:333e42.
[4] Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual
screening for drug discovery: methods and applications. Nat Rev Drug Discov
2004;3:935e49.
[5] Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645e6.
[6] Harvey AL. Natural products in drug discovery. Drug Discov Today 2008;13:
894e901.
[7] Shin BK, Kwon SW, Park JH. Chemical diversity of ginseng saponins from
Panax ginseng. J Ginseng Res 2015;39:287e98.
[8] Namba T, Matsushige K, Morita T, Tanaka O. Saponins of plants of Panax
species collected in central Nepal and their chemotaxonomical signiﬁcance.
I. Chem Pharm Bull 1986;34:730e8.
[9] Sanada S, Kondo N, Shoji J, Tanaka O, Shibata S. Studies on the saponin of
ginseng. I. Structures of ginsenoside-Ro, -Rb1, -Rc, and -Rd. Chem Pharm Bull
1974;22:421e8.
[10] Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin
Med 2010;5:20.
[11] Chen X, Ung CY, Chen Y. Can an in silico drug-target search method be used to
probe potential mechanisms of medicinal plant ingredients? Nat Prod Rep
2003;20:432e44.
[12] Cai J, Han C, Hu T, Zhang J, Wu D, Wang F, Liu Y, Ding J, Chen K, Yue J, et al.
Peptide deformylase is a potential target for anti-Helicobacter pylori drugs:
reverse docking, enzymatic assay, and X-ray crystallography validation. Pro-
tein Sci 2006;15:2071e81.
[13] Gao Z, Li H, Zhang H, Liu X, Kang L, Luo X, Zhu W, Chen K, Wang X, Jiang H.
PDTD: a web-accessible protein database for drug target identiﬁcation. BMC
Bioinformatics 2008;9:104.
[14] Zahler S, Tietze S, Totzke F, Kubbutat M, Meijer L, Vollmar AM, Apostolakis J.
Inverse in silico screening for identiﬁcation of kinase inhibitor targets. Chem
Biol 2007;14:1207e14.
[15] Chen YZ, Ung CY. Prediction of potential toxicity and side effect protein tar-
gets of a small molecule by a ligandeprotein inverse docking approach. J Mol
Graph Mod 2001;20:199e218.
[16] Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S,
Shoemaker BA, et al. PubChem Substance and Compound databases. Nucl
Acids Res 2016;44:D1202e13.
[17] Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP,
Knoll EH, Shelley M, Perry JK, et al. Glide: a new approach for rapid, accurate
docking and scoring. 1. Method and assessment of docking accuracy. J Med
Chem 2004;47:1739e49.
[18] Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL.
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment
factors in database screening. J Med Chem 2004;47:1750e9.
[19] Choi YJ, Lee HJ, Kang DW, Han IH, Choi BK, Cho WH. Ginsenoside Rg3 induces
apoptosis in the U87MG human glioblastoma cell line through the MEK
signaling pathway and reactive oxygen species. Oncol Rep 2013;30:1362e70.
[20] Sathishkumar N, Karpagam V, Sathiyamoorthy S, Woo MJ, Kim YJ, Yang DC.
Computer-aided identiﬁcation of EGFR tyrosine kinase inhibitors using gin-
senosides from Panax ginseng. Comput Biol Med 2013;43:786e97.
[21] Zhou Q, Jiang L, Xu C, Luo D, Zeng C, Liu P, Yue M, Liu Y, Hu X, Hu H. Ginse-
noside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res
2014;133:57e65.
[22] Joo CN, Kim SJ. Effect of ginseng components (ginsenosides and fat soluble
fraction) on rat liver glucokinase activity. Korean Soc Ginseng 1994;18:1e9.
[23] Davis RJ. The mitogen-activated protein kinase signal transduction pathway.
J Biol Chem 1993;268:14553e6.
[24] Singh P, Bast F. In silico molecular docking study of natural compounds on
wild and mutated epidermal growth factor receptor. Med Chem Res 2014;23:
5074e85.
[25] Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, Liu Y. EGFR signaling-dependent
inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol 2014;35:
5593e8.g to identify potential targets for ginsenosides, Journal of Ginseng
J Ginseng Res 2016;-:1e66[26] Banner DW, Hadváry P. Crystallographic analysis at 3.0-Å resolution of the
binding to human thrombin of four active site-directed inhibitors. J Biol Chem
1991;266:20085e93.
[27] Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M, Scagliotti GV.
Aurora kinase A expression is associated with lung cancer histological-
subtypes and with tumor de-differentiation. J Transl Med 2011;9:100.
[28] Umene K, Banno K, Kisu I, Yanokura M, Nogami Y, Tsuji K, Masuda K, Ueki A,
Kobayashi Y, Yamagami W, et al. Aurora kinase inhibitors: potential molecular
targeted drugs for gynecologic malignant tumors (review). Biomed Rep
2013;1:335e40.
[29] Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholines-
terases by irinotecan (CPT-11). Mol Pharm 1999;56:1346e53.Please cite this article in press as: Park K, Cho AE, Using reverse dockin
Research (2016), http://dx.doi.org/10.1016/j.jgr.2016.10.005[30] Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of
adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab
1999;84:4274e7.
[31] Bryła J, Lietz T, Jarzyna R, Michalik M, Pietkiewicz J. Differential in vivo and
in vitro effect of gentamicin on glutamate synthesis and glutamate deami-
nation in rabbit kidney-cortex tubules and mitochondria. Pharmacol Res
1992;26:367e75.
[32] Nag SA, Qin JJ, Wang W, Wang MH, Wang H, Zhang R. Ginsenosides as anti-
cancer agents: in vitro and in vivo activities, structureeactivity relationships,
and molecular mechanisms of action. Front Pharm 2012;3:25.
[33] Kim JH. Cardiovascular diseases and Panax ginseng: a review on molecular
mechanisms and medical applications. J Ginseng Res 2012;36:16e26.g to identify potential targets for ginsenosides, Journal of Ginseng
